Antibody neutralizing human respiratory syncytial virus
Kalpit A. Vora, Yardley, PA (US); Kara S. Cox, Harleysville, PA (US); Aimin Tang, Lansdale, PA (US); Zhifeng Chen, Warrington, PA (US); Daniel DiStefano, Harleysville, PA (US); Lan Zhang, Chalfont, PA (US); and Hua-Poo Su, Phoenixville, PA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed on Dec. 13, 2022, as Appl. No. 18/065,172.
Application 15/928,438 is a division of application No. 15/335,560, filed on Oct. 27, 2016, granted, now 9,963,500, issued on May 8, 2018.
Application 18/065,172 is a continuation of application No. 17/115,510, filed on Dec. 8, 2020, granted, now 11,566,065.
Application 17/115,510 is a continuation of application No. 16/434,729, filed on Jun. 7, 2019, granted, now 11,008,380, issued on May 18, 2021.
Application 16/434,729 is a continuation of application No. 15/928,438, filed on Mar. 22, 2018, granted, now 10,358,480, issued on Jul. 23, 2019.
Claims priority of provisional application 62/367,359, filed on Jul. 27, 2016.
Claims priority of provisional application 62/247,841, filed on Oct. 29, 2015.
Prior Publication US 2023/0212269 A1, Jul. 6, 2023
1. A method of preventing or treating an RSV infection in an elderly human subject, comprising administering to the subject an effective amount of an antibody or antigen binding fragment that binds to human RSV F protein, wherein the antibody or antigen binding fragment comprises a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6.